ABSTRACT
Resumo A Covid-19 é uma doença respiratória potencialmente grave causada pelo RNA vírus SARS-CoV-2, que apresenta risco aumentado de tromboembolismo venoso (TEV). Sua fisiopatologia está relacionada a processo inflamatório exacerbado e a coagulopatia associada, verificada pelo aumento do D-dímero, do fibrinogênio e dos produtos da degradação da fibrina. Sua ocorrência deve ser monitorada, prevenida e tratada de acordo com as recomendações e diretrizes existentes. Devido a sua associação com as formas mais graves da doença e morte, alguns grupos vêm propondo uma conduta profilática e terapêutica mais agressiva. Entretanto, não existe uma definição quanto ao risco-benefício desse tipo de conduta, devendo ser avaliada individualmente e de forma multidisciplinar. Neste estudo, revisamos os principais estudos e evidências disponíveis até o momento sobre o diagnóstico, profilaxia e recomendações de tratamento do TEV em pacientes COVID-19.
Abstract COVID-19 is a potentially serious respiratory disease caused by the SARS-CoV-2 virus that involves an increased risk of venous thromboembolism (VTE). Its pathophysiology is apparently related to an exacerbated inflammatory process and coagulopathy, verified by an increase in D-dimer, fibrinogen, and fibrin degradation products. Occurrence must be monitored, prevented, and treated according to existing recommendations and guidelines. The increased risk of thrombosis, and the association between this phenomenon and the most severe forms of the disease and death have prompted some groups to propose a more aggressive prophylactic and therapeutic approach. However, the risk-benefit profile of this type of conduct has not been defined and cases must be assessed individually, with a multidisciplinary approach. In this study, we review the main studies and evidence available to date on diagnosis, prophylaxis, and treatment of venous thromboembolism in COVID-19 patients.
Subject(s)
Thrombosis , Disseminated Intravascular Coagulation/prevention & control , Betacoronavirus , Anticoagulants , Coronavirus InfectionsABSTRACT
Clinical studies in the treatment of 54 children suffering from DHF with a combination of dipyridamole and ASA as an adjuvant of our standard therapy consisted of fluid, electrolytes, blood, plasma and plasma expanders were evaluated. Heparin was administered in cases of DIC. It appeared that dipyridamole and ASA did not change the mortality significantly, but it prevented the progress of the severity of the disease from grade I and II to grade III and IV.